INTRODUCTION AND OBJECTIVES: Antimuscarinic are the current pharmacological mainstay for overactive bladder (OAB). However, adverse events resulting from antimuscarinics are inevitable in some patients. Discontinuation rates of 70% to 90% within the first year of therapy have been reported for various OAB medications, because the therapy did not produce the treatment bene?t expected. Mirabegron, which acts as a subtype of relaxation of detrusor, appeared on the Japanese market in 2011, and it provides a new treatment option for OAB. Currently, there are few published studies on the long-term persistence with drug therapy among OAB patients. The purposes of this study were to evaluate OAB pharmacotherapy adherence.
INTRODUCTION AND OBJECTIVES:
There is a debate on the need for complete or partial removal of midurethral slings (MUS) in women presenting with pain only after sling placement. We reviewed our staged approach to determine the rates of success after each procedure.
METHODS: Following IRB approval, a prospectively maintained database of women requiring suburethral sling removal (SSR) for pain only between 2005 and 2015 was queried. Data reviewed by a third party investigator not involved in patient care from an electronic medical record included: demographics, type of MUS, onset and location of pain, evaluation (including imaging), surgical findings, and short and long term outcomes, including additional procedures for additional mesh sling arm removal (retropubically for TVT/SPARC and groin dissection for TOT). Pain was ranked by self-report as no pain, improved, same or worse. SSR was performed vaginally with the goal of excising just the suburethral portion of the MUS.
RESULTS: Of 47 patients, 21 (44.6%) were rendered pain-free after SSR alone (Table 1 . Flow chart). Among those with residual pain (26), 12 elected conservative management while 7 opted for a secondary retropubic arms removal and another 7 for a secondary translabial obturator arm dissection. None were found to have infected slings. Among the 14 who underwent a secondary procedure for residual pain after SSR, 5 (36%) were rendered pain-free, 3 (21%) improved, 5 (36%) reported the same amount of pain and 1 (7%) had worse pain. After this secondary procedure, 6 women opted for PMR management. Ultimately, despite staged approach and PMR management, 1 (7%) remained with invalidating pain.
CONCLUSIONS: Nearly half of women operated for pain only after MUS placement find durable relief after an SSR procedure alone, whereas another 30% elected additional removal of residual mesh arms either suprapubically or in the obturator area.
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